Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Tuesday 04 January, 2022

Ergomed plc

Total Voting Rights and Block Listing Return

RNS Number : 2516X
Ergomed plc
04 January 2022
 

 

 

Total Voting Rights and Block Listing Return

 

 

Total Voting Rights

 

Guildford, UK - 4 January 2022 : In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

 

The Company's issued share capital as at 31 December 2021 consisted of 49,138,071 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

 

Block Listing Six Monthly Return

 

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

1 July 2021

To:

31 December 2021

Balance of unallotted securities under scheme(s) from previous return:

1,466,400

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

600,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

158,223

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,908,177

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

1,500,000 ordinary shares of 1p each - 31 December 2019

600,000 ordinary shares of 1p each - 7 July 2021

Total number of securities in issue at the end of the period

49,138,071 ordinary shares of 1p each

 

Name of contact:

Nick Roberts - Head of Group Reporting

Telephone number of contact:

+44 (0) 1483 503 205

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal 

[email protected]

Angela Gray / Lucy Featherstone




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit:  http://ergomedplc.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBXLLBLFLXBBD

a d v e r t i s e m e n t